Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Consensus Target Price from Analysts

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have earned an average rating of “Buy” from the eight research firms that are presently covering the firm, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $81.29.

GPCR has been the subject of a number of analyst reports. William Blair assumed coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an “outperform” rating for the company. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Stifel Nicolaus initiated coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target on the stock. Finally, JMP Securities restated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds have recently modified their holdings of the business. ANTIPODES PARTNERS Ltd raised its stake in Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after purchasing an additional 553 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after purchasing an additional 1,122 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Structure Therapeutics during the fourth quarter valued at about $34,000. Assetmark Inc. lifted its stake in shares of Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after buying an additional 719 shares during the period. Finally, FNY Investment Advisers LLC acquired a new stake in Structure Therapeutics during the fourth quarter worth about $40,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Stock Performance

Shares of GPCR opened at $23.53 on Friday. The firm has a market cap of $1.35 billion, a PE ratio of -31.80 and a beta of -2.75. The firm’s 50 day moving average price is $26.10 and its 200 day moving average price is $33.22. Structure Therapeutics has a twelve month low of $19.61 and a twelve month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. On average, sell-side analysts anticipate that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.